Bioventus Inc.

Bioventus Inc. Earnings Recaps

BVS Health Care 2 recaps
Next earnings: March 4, 2027 (estimated) · full calendar
Q3 2026 Nov 4, 2026

Bioventus shares fell 16.8% after earnings, with the most evident pressure point being softness in bone graft substitutes, down 6%, despite 3% overall revenue growth. The transcript also points to continued investment in growth initiatives, while the outlook details needed to assess the guidance update are not included.

Key takeaways
  • Q3 revenue grew 3%; pain treatments rose 6%, partly offset by a 6% decline in bone graft substitutes.
  • PRP disposable-kit revenue exceeded capital-placement revenue for the first time, and the company secured exclusive sports-medicine rights for its PRP solution.
  • PNS indicators improved: trial-to-permanent conversion exceeded plan, time to permanent placement shortened, and physicians trained increased by more than 50% quarter over quarter.
  • Ultrasonics delivered double-digit revenue growth; international revenue rose 16%.
  • Adjusted EBITDA margin was 20%, up 70 basis points year over year; management expects full-year margin to be above the prior-year level.
Q2 2026 Aug 8, 2026

Bioventus shares rose 4.2% post-earnings, driven by better-than-expected revenue growth and encouraging momentum across key growth segments, particularly Pain Treatments. The reaffirmation of full-year guidance and positive strategic developments underpinned investor optimism.

Key takeaways
  • Q2 revenue increased 4%, led by strong double-digit growth in the Pain Treatments segment, notably the HA franchise and DUROLANE product.
  • Year-to-date HA business outperformed expectations, enabling reinvestment into growth areas like PRP, PNS, Ultrasonics, and International markets.
  • Leading indicators such as accelerating PRP capital placements, increased surgeon adoption of PNS, and growing Ultrasonics disposable usage signal strengthening market traction.
  • International segment showing accelerating momentum due to targeted market focus and new talent additions, with expectations for strong double-digit growth in H2 and full year.
  • Company reiterated full-year guidance and disclosed a strategic review including potential sale options, reflecting management’s commitment to maximizing shareholder value.